Learning objectives
§ To compare and contrast the molecular and physicochemical properties of gadobenate dimeglumine (Gd-BOPTA, MultiHance) with conventional gadolinium (Gd) contrast agents § To review the impact of the unique physicochemical properties of gadobenate dimeglumine – transient serum protein binding capacity, markedly increased r1 and r2 relaxivity, and dual ECF/liver imaging capability – on contrast-enhanced magnetic resonance (MR) imaging of the central nervous system (CNS), vasculature, breast, liver, and heart § To summarize safety data accumulated following a decade of use in both clinical trials and...
Background
Gadobenate dimeglumine (MultiHance, Gd-BOPTA; Bracco Imaging Spa, Milan, Italy) is an extracellular gadolinium (Gd) contrast agent with the capacity for transient interaction with serum proteins, notably serum albumin. The result of this interaction is markedly higher r1 and r2 relaxivities at all magnetic field strengths compared with conventional Gd contrast agents [1,2]. Gadobenate dimeglumine was originally approved for contrast-enhanced magnetic resonance (MR) imaging of the liver in Europe in 1997 and was first administered as part of routine clinical practice in 1998 [3]. A decade...
Imaging findings OR Procedure details
MOLECULAR AND PHYSICOCHEMICAL PROPERTIES Molecular Structure - Gadobenate dimeglumine comprises a linear, ionic chelate of the paramagnetic Gd3+ ion (Gd-BOPTA), salified with two molecules of meglumine. The structure resembles that of gadopentetate dimeglumine (Magnevist®, Gd-DTPA), apart from the addition of a hydrophobic benzyloxymethyl substituent (Figure 1). This substituent confers on gadobenate dimeglumine two properties that differentiate it from gadopentetate dimeglumine and the other conventional Gd contrast agents: markedly higher r1 and r2 relaxivity, and a dual route of elimination through both the renal and hepatobiliary...
Conclusions
Gadobenate dimeglumine demonstrates unique benefits for many clinical applications. The higher r1 relaxivity of gadobenate dimeglumine permits increased contrast enhancement and greater diagnostic information compared to standard-relaxivity agents at equivalent dose, and offers the potential for accurate diagnostic performance with lower doses. Over the past decade many clinical studies, both inter- and intraindividual, have demonstrated improved performance for gadobenate dimeglumine when compared to conventional Gd contrast agents for many routine MR applications. Published data from clinical trials and postmarketing surveillance have confirmed the excellent safety...
Personal Information
Miles A. Kirchin, PhD Bracco Imaging Milan, Italy 20134Tel:
[email protected] John R. Parker Bracco Diagnostics Inc., Princeton, NJ Tel: (609)
[email protected] Cindy Schultz, PhD Corporate Medical Communications Bracco Diagnostics, Inc. Princeton, NJ 08540 USATel:
[email protected]
References
1. de Haën C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999;23(suppl 1):S161-S168. 2. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221. Erratum in Invest Radiol. 2006;41:859. 3. Shellock FG, Parker JR, Venetianer...